Challenges in Extrapolating Healthy Volunteer Pharmacokinetics to Oncology Populations: Advocating for a Holistic Perspective

Documenti analoghi

• Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers
  di: Jumar Etkins, et al.
  Pubblicazione: (2025)
• Correction to “Genotype‐Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers”
  Pubblicazione: (2026)
• Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions
  di: Min Xiao, et al.
  Pubblicazione: (2025)
• Ecopipam, a Dopamine D1 Receptor Antagonist: Pharmacokinetics, Mass Balance, and Metabolism in Healthy Volunteers
  di: Virginia D. Schmith, et al.
  Pubblicazione: (2026)
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial
  di: Thomas Capozza, et al.
  Pubblicazione: (2025)